Cellular immunity in melanoma patients with organic metastases (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Cellular immunity in melanoma patients with organic metastases (Meeting abstract).

Melanoma Res; 3:47 1993. Unique Identifier : AIDSLINE ICDB/95607302
Wehner-Caroli J; Bogenschutz O; Rassner G; Fierlbeck G; Department of Dermatology, University of Tubingen, Germany

Abstract: In patients with malignant melanoma stage IV (UICC 1979) peripheral mononuclear blood cells were investigated by flow cytometric analysis. We evaluated 30 patients in an advanced stage of malignant melanoma compared to a control group of 35 healthy adults. For statistic analysis the student T-test (significant level p less than pr equal to 0.05) was used. Percentages of T- (CD3+ cells) and B-lymphocytes (CD-20+ cells), T-helper cells (CD4+ cells), cytotoxic T-cells (CD8+ cells), CD4:CD8 ratio, some cell subsets (CD4+, CD45R+ 'naive' T-cells and CD4+, CDw29+ 'memory' T-cells), natural killer (NK) cells (CD3-, CD16+, CD56+ cells) and markers of activation (HLA-DR, HLA-DQ, CD25 [IL-2-receptor] and CD54 [ICAM-I]) were determined. On monocytes the expression of HLA-DR and HLA-DQ was investigated. No significant changes could be found in peripheral blood leukocyte phenotyping except an increase of CD25 [IL-2-receptor] expression on T-cells (TCR-1+, CD25+ cells, activated T-cells). Neither differential blood count nor absolute leukocyte numbers showed any significant changes. Our results show it is noteworthy that there is no measurable general immunodeficiency in stage IV melanoma patients.
Keywords: Antigens, CD/METABOLISM CD4-CD8 Ratio Human HLA Antigens/METABOLISM *Immunity, Cellular Lymphocyte Subsets Melanoma/*IMMUNOLOGY/PATHOLOGY Neoplasm Metastasis ABSTRACTKWDantigens,cd/metabolismcd4-cd8ratiohumanhlaantigens/metabolismKWDimmunity,cellularlymphocytesubsetsmelanoma/KWDimmunology/pathologyneoplasmmetastasisabstract
950630
M9561165

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .